Written Question·Department of Health and Social Care·UIN 109569

Immunotherapy

Tabled: 29 January 2026

Answered: 4 February 2026

Question

Kevin Hollinrake

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of NICE's draft guidance on brexucabtagene autoleucel on (a) the Life Sciences Strategy and (b) outcomes for patients with rare cancers.

Answer

Dr Zubir Ahmed

The Government remains committed to the ambitions set out in the Life Sciences Sector Plan, which set out an ambition that by 2030, we will be one of the top three fastest places in Europe for patient access to medicines. We will achieve this by reducing ...

ⓘ

This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 109569) →